Skip to main content
Premium Trial:

Request an Annual Quote

Precision Oncology Resources: Recent webinars

May
26
2021

Sponsored by Lexogen

CaTCH it if you can! CRISPRa-based Exploration of Therapy Resistant Cell Clones

The emergence of cell clones that are resistant to targeted therapies poses a significant issue in the treatment of metastatic melanoma. While founding clones are often extremely rare in a starting population, their isolation and characterization hold unique potential for understanding disease processes, uncovering novel biomarkers, and developing therapeutic concepts. 

In this webinar, Christian Umkehrer of Vienna’s Research Institute of Molecular Pathology describes the development and application of CaTCH (CRISPRa Tracing of Clones in Heterogeneous Cell Populations), which combines precise mapping of the lineage history of millions of cells with the ability to isolate any given clone alive from a complex population based on genetic barcodes. 

CaTCH enables the retrospective isolation and analysis of founding clones from heterogeneous cell populations prior to evolutionary selection. The approach uses QuantSeq 3’ mRNA-Seq to characterize the isolated clones by efficiently profiling gene expression.

In his presentation Christian Umkehrer will explain how CaTCH can:

  • be used to trace and isolate therapy-resistant clones from complex cancer cell populations in vitro.
  • be applied to in vivo studies by investigating the origins of resistance to clinically relevant RAF/MEK inhibition in an immunocompetent melanoma mouse model.
  • address further fundamental questions in basic and translational research (e.g., how cell identity states and trajectories are determined in therapy resistance, metastasis formation, or somatic cell re-programming).

Sponsored by

Apr
27
2021

Sponsored by Biognosys

Oncology in the Time of COVID-19: Quantitative Proteomic Analysis of Anti-IL6 Treated Patients

This webinar, the first in our Next-Generation Proteomics for Precision Oncology series, will discuss how proteomics can help overcome the challenges of treating COVID-19 patients with oncologic comorbidities.

Recent advances in mass spectrometry-based proteomics have fostered a more precise, deep, and more functional look into clinical phenotypes. Going beyond traditional genomics, proteomics enables more relevant, quantitative, and informative understanding of diseases and treatments.

Jean-Marie Michot, a medical oncologist at Gustave Roussy Institute and Vito Dozio, Scientific Project Manager at Biognosys, will share a study that illustrates the promise of proteomics in understanding responses to new therapies such as anti-IL-6-based treatment and the impact of comorbidities on clinical outcomes.

They will discuss the results of a joint project in which serum from a cohort of patients infected with COVID-19 was submitted for analysis using the Biognosys HRM discovery proteomics platform. They will share details of proteomic profiles associated with clinical outcome, comorbidities, and the response to anti-IL6 treatment, which provide a comprehensive picture of the potential of using next-generation proteomics to enhance personalized medicine. 

About The Series: Next-Generation Proteomics for Precision Oncology

This webinar series will highlight recent advancements in the proteomics field and the impact of proteomics on clinical research in oncology.

Sponsored by

Apr
08
2021

Sponsored by Roche

Interpretation of Comprehensive Genomic Profiling from ctDNA Through Clinical Decision Support

Genomics is central to the precision oncology cascade. After tissue or blood is subjected to next-generation sequencing (NGS) and bioinformatics analysis, the alterations detected must be annotated and interpreted within the context of the individual patient.

This webinar will discuss a single-center prospective interventional study that evaluated the success of a targeted therapy selected by profiling of ctDNA and tissue in patients with advanced and refractory carcinoma.

Samantha Hasenleithner of the Medical University of Graz will discuss the approach, which reflects a true clinical scenario in which both plasma and tissue analytes help inform treatment decisions. Nevertheless, this workflow poses challenges for clinicians in selecting the appropriate treatment.

Clinical decision support may help streamline these variant interpretation and treatment matching workflows, and Dr. Hasenleithner will discuss an evaluation of three such tools and her team’s experience with the Navify Mutation Profiler*.

*For Research Use Only.  Not for use in diagnostic procedures in the US.

Sponsored by

Mar
30
2021

Sponsored by Menarini Silicon Biosystems

Circulating Tumor Cells in Breast Cancer: Understanding a Validated Diagnostic Tool for Precision Medicine

This webinar will provide an overview of the current state of circulating tumor cell (CTC) enumeration for clinical use in metastatic breast cancer.

Dr. Massimo Cristofanilli, Associate Director of Translational Research and Precision Medicine at Robert Lurie Cancer Center, Northwestern University, will review the evidence, as well as clinical case studies demonstrating how CTCs can be utilized in clinical practice and clinical research studies in metastatic breast cancer. 

A prominent figure in the liquid biopsy field, Dr. Cristofanilli led a pivotal study demonstrating the prognostic value of CTC enumeration using the semiautomated CellSearch technology. CellSearch has been cleared by the US Food and Drug Administration for detecting and enumerating circulating tumor cells to help manage patients with metastatic breast, prostate, and colorectal cancers.

Dr. Cristofanilli will discuss future developments and applications of CTCs in oncology. The session will wrap up with a live Q&A with Dr. Cristofanilli.

Sponsored by

Mar
25
2021

Sponsored by Foundation Medicine

Virtual Molecular Tumor Board Series: What to Do with a ‘Negative’ Molecular Panel Case

In this session, the fourth in the Precision Oncology News Virtual Molecular Tumor Board Series, our expert panelists will review patient cases in which genomic profiling identified no clear molecular markers to help guide personalized therapy.

The application of comprehensive genomic profiling (CGP) in patients with metastatic solid tumors aims to identify therapeutic options that were not otherwise evident with standard workup. However, CGP -- even when it analyzes patient samples against 500+ potential mutations — does not always identify an actionable target.  In these cases, clinicians still need to develop a care plan based on best evidence and individual patient goals.

Our panel will discuss several of these cases in detail and recommend next steps.

The session will wrap up with a live Q&A in which attendees can discuss the cases with the Virtual Molecular Tumor Board panelists.

About The Series

The Virtual Molecular Tumor Board Series is an interactive and educational online program intended to highlight the key role that molecular tumor boards play in implementing precision oncology.

The series will underscore the collaborative nature of genomic medicine by assembling a multidisciplinary panel of experts who will meet virtually for four one-hour sessions. In each session, the panel will review the genomic and clinical evidence for anonymized patients who have had their tumors sequenced as part of clinical management. The panel will discuss each case and recommend a course of treatment.

Precision Oncology News would like to thank Clariifi for assistance in planning and executing this educational webinar series.


Sponsored by

field_file_image_alt_text_value
Mar
23
2021

Sponsored by Roche

ctDNA MRD Detection and Personalized Oncogenomic Analysis in Colorectal Cancer

This webinar will discuss findings from the study, in which molecular residual disease (MRD) was assessed using circulating tumor DNA (ctDNA) without prior mutational knowledge in oligometastatic colorectal cancer (CRC) patients who had received neoadjuvant chemotherapy. This study also investigated urine as an alternative analyte for ctDNA MRD detection.

Dr. Aadel Chaudhuri of Washington University will share details of the study, which applied Avenio targeted next-generation sequencing (NGS) *to plasma, tumor and urine samples acquired on the day of curative-intent surgery from prospectively enrolled oligometastatic CRC patients.

The study demonstrated that tumor-naïve plasma ctDNA analysis can sensitively and specifically detect MRD in patients with oligometastatic CRC after neoadjuvant chemotherapy, while urine-based ctDNA MRD detection is less sensitive than plasma. Dr. Chaudhuri will discuss these findings in detail.

* For Research Use Only.  Not for use in diagnostic procedures.

Sponsored by

Mar
11
2021

Sponsored by Foundation Medicine

Virtual Molecular Tumor Board Series: Gene Fusions as Druggable Targets

In this session, the third in the Precision Oncology News Virtual Molecular Tumor Board Series, our expert panelists will review patient cases in which genomic profiling has identified gene fusions that may or may not serve as druggable targets.

Precision medicine has been focused on the presence of activating mutations or gene amplifications. However, recent data has shown that the presence of gene fusions also offer a unique treatment opportunity, with the potential for durable clinical responses.

Our panel will discuss several such clinical cases in detail and recommend a course of treatment based on the genomic profiles of the patients.

The session will wrap up with a live Q&A in which attendees can discuss the cases with the Virtual Molecular Tumor Board panelists.

About The Series

The Virtual Molecular Tumor Board Series is an interactive and educational online program intended to highlight the key role that molecular tumor boards play in implementing precision oncology.

The series will underscore the collaborative nature of genomic medicine by assembling a multidisciplinary panel of experts who will meet virtually for four one-hour sessions. In each session, the panel will review the genomic and clinical evidence for anonymized patients who have had their tumors sequenced as part of clinical management. The panel will discuss each case and recommend a course of treatment.

Precision Oncology News would like to thank Clariifi for assistance in planning and executing this educational webinar series.

Sponsored by

field_file_image_alt_text_value
Feb
25
2021

Sponsored by Foundation Medicine

Virtual Molecular Tumor Board Series: Common Driver Mutations in ‘Off-Label’ Tumor Types

In this session, the second in the Precision Oncology News Virtual Molecular Tumor Board Series, our expert panelists will review cases in which patient genomic profiles exhibit common driver mutations in tumor types considered “off label” for targeted therapies associated with those mutations.

US Food and Drug Administration approvals for targeted anticancer therapy are most often for specific types of cancer that possess specific driver mutations. However, the broad application of comprehensive genomic profiling has identified the presence of potential “druggable” driver mutations in malignancies for which FDA approval is not yet obtained.

Our panel will discuss several such clinical cases in detail and recommend a course of treatment based on the genomic profiles of the patients.

The session will wrap up with a live Q&A in which attendees can discuss the cases with the Virtual Molecular Tumor Board panelists.

About The Series 

The Virtual Molecular Tumor Board Series is an interactive and educational online program intended to highlight the key role that molecular tumor boards play in implementing precision oncology.

The series will underscore the collaborative nature of genomic medicine by assembling a multidisciplinary panel of experts who will meet virtually for four one-hour sessions. In each session, the panel will review the genomic and clinical evidence for anonymized patients who have had their tumors sequenced as part of clinical management. The panel will discuss each case and recommend a course of treatment.

Precision Oncology News would like to thank Clariifi for assistance in planning and executing this educational webinar series.


Sponsored by

field_file_image_alt_text_value
Feb
11
2021

Sponsored by Foundation Medicine

Virtual Molecular Tumor Board Series: HRD and DNA Damage Repair

In this session, the first in the Precision Oncology News Virtual Molecular Tumor Board Series, our expert panelists will review patient cases in which genomic profiling has identified biomarkers related to homologous recombination deficiency and DNA damage repair.

Initial interest in homologous recombination genes was focused on pathologic mutations associated with risk of inherited breast, prostate, pancreatic, and/or gynecological malignancies. HRD has recently emerged as a biomarker to predict sensitivity to PARP inhibitors, and the identification of these alterations has become important, accordingly.

Our panel will discuss several such clinical cases in detail and recommend a course of treatment based on the genomic profiles of the patients.

The session will wrap up with a live Q&A in which attendees can discuss the cases with the Virtual Molecular Tumor Board panelists.

About The Series 

The Virtual Molecular Tumor Board Series is an interactive and educational online program intended to highlight the key role that molecular tumor boards play in implementing precision oncology.

The series will underscore the collaborative nature of genomic medicine by assembling a multidisciplinary panel of experts who will meet virtually for four one-hour sessions. In each session, the panel will review the genomic and clinical evidence for anonymized patients who have had their tumors sequenced as part of clinical management. The panel will discuss each case and recommend a course of treatment.

Precision Oncology News would like to thank Clariifi for assistance in planning and executing this educational webinar series.



Sponsored by

field_file_image_alt_text_value
Dec
02
2020

Sponsored by Qiagen

PIK3CA Mutations in Advanced Breast Cancer: The Vital Role of Tissue and Plasma Companion Diagnostics

The Phosphoinositide 3-Kinase (PI3K) pathway is one of the most frequently altered pathways in human cancer and plays a significant role in disease progression and resistance to endocrine therapy.

In this webinar, Dr. Lawrence Weiss from NeoGenomics will discuss his experience with the validation and implementation of testing for actionable PIK3CA mutations using the therascreen PIK3CA RGQ PCR Kit.

The webinar will provide an overview of an innovative approach to detecting PIK3CA mutations by testing either tissue or plasma samples and the benefits this brings to breast cancer care. An FDA-approved companion diagnostic test, the therascreen PIK3CA RGQ PCR Kit helps clinicians identify actionable PIK3CA mutations in breast cancer cases to inform patient treatment choices.

The webinar will focus on the following topics:

  • Overview of HR+/HER2- breast cancer progression and resistance to endocrine therapy.
  • The biology and activation of the PI3K pathway and its role in cancer.
  • Validation and implementation of the therascreen PIK3CA RGQ PCR Kit for testing of both formalin-fixed, paraffin-embedded tissue and plasma samples.
  • The provision of Day 1 availability of PIK3CA mutation companion diagnostic testing.

The therascreen PIK3CA RGQ PCR Kit is intended for in vitro diagnostic use. Products and product claims may differ from country to country based on regulations and approvals. Contact your country representative for further details.

Sponsored by

field_file_image_alt_text_value
Nov
23
2020

Sponsored by Inivata

Liquid Biopsy to Understand Resistance Mechanisms in Non-Small Cell Lung Cancer

In non-small cell lung cancer (NSCLC), liquid biopsy allows detection of driver mutations and can shed light on the development of resistance mutations during treatment. 

This webinar will provide an overview of several studies that used a NSCLC liquid biopsy test, InVisionFirst-Lung. The assay enabled the analysis of markers present at the beginning of treatment and at progression, providing valuable insights into resistance to ALK/ROS1 and BRAF targeted agents.

Sponsored by

field_file_image_alt_text_value
Nov
09
2020

Sponsored by Akoya Biosciences

The Tumor Neighborhood Watch: How Spatial Architecture and Cellular Neighborhoods Correlate to Colorectal Cancer Outcomes

Most recent single-cell and spatial biology studies have focused on the network of interactions between different cell types and their spatial context. However, studying tumor biology at two different levels — the interacting cell types as well as the tissue regions within which they are organized — can give further insight into tumor progression and immunotherapy response.

Dr. Garry Nolan and his team at Stanford University collaborated with the University of Bern to conduct deep single-cell phenotyping and spatial analysis on a cohort of colorectal cancer formalin-fixed, paraffin-embedded samples using the CODEX (CO-Detection by indEXing) platform from Akoya Biosciences. As a result, the authors discovered nine distinct cellular neighborhoods, each uniquely composed of certain immune and cancer cell types. These cellular neighborhoods were found to interact with one another in a manner that correlated with disease progression and prognosis.

In this webinar, Dr. Nolan will discuss the findings from the study and present an analytical framework to analyze high-dimensional imaging data that can reveal new insights into how the tumor microenvironment is organized.

Learning objectives:

  • How to use high-dimensional imaging to study tumor biology at the single-cell and tissue architecture levels
  • How spatial interactions between cellular aggregates in the tumor microenvironment contribute to disease progression and prognosis in colorectal cancer

Sponsored by

field_file_image_alt_text_value
Nov
05
2020

Sponsored by Roche

Clinical Insights from Multi-omic Studies on Esophageal Cancer

In this webinar, Rebecca Fitzgerald of the Hutchison-MRC Research Center at the University of Cambridge, will give a broad overview of the epidemiology and clinical features of esophageal cancer. Focussing on esophageal adenocarcinoma she will discuss the progress that has been made in understanding the molecular landscape of this cancer from whole genome sequencing and RNA sequencing data. She will describe how although the driver gene landscape is highly heterogeneous the mutational signatures and cell signalling pathways converge to indicate the likely cause and vulnerabilities in esophageal adenocarcinoma which pave the way for new therapy approaches.

In the final part of the webinar Rebecca will discuss how earlier detection of relapse and indicators of response to therapy would help to tailor treatment. Blood biopsy to detect circulating tumor DNA is one such approach and Dr. Fitzgerald will present data to show the potential of a ctDNA mutation panel to detect relapse post-surgery in patients with esophageal adenocarcinoma in a retrospective study.

Sponsored by

Nov
03
2020

Sponsored by Agilent

A Streamlined Targeted NGS Workflow for Comprehensive Genomic Profiling of Different Tumor Samples

Molecular tumor profiling has provided extensive value, both in tumor biology and oncology, with the development of new technologies to identify biomarkers. While conventional technologies, such as FISH and PCR, allow accurate low-throughput detection (e.g., EML4-ALK fusion), next-generation sequencing-based approaches enable comprehensive and simultaneous identification of various alterations (single nucleotide variants, insertions/deletions, fusions, copy number alterations) and genomic signatures (microsatellite instability, tumor mutational burden).

Compared to conventional technologies, NGS-based approaches overcome the challenge of limited materials and reduce the turnaround time. However, further improvements are still needed due to the complex structure of the genome, including repetitive regions and high GC/AT content.

In this webinar, Dr. Judith Müller-Eisert of NEO New Oncology will discuss a collaboration with Agilent Technologies to develop several hybrid capture-based assays for various tumor entities using the SureSelect XT HS2 chemistry. She will share details of the kit’s performance and discuss its use as a powerful tool for cancer profiling.

For Research Use Only. Not for use in diagnostic procedures.

Sponsored by

Oct
29
2020

Sponsored by Illumina

How to Train Your DRAGEN for Pathology Informatics

Illumina’s BaseSpace Sequence Hub (BSSH) supports primary and secondary analysis of massively parallel sequencing data and can be applied to gene panel data that is generated as part of a clinical cancer assay performed in a pathology lab.

In this webinar, Lynn Fink of Xing Cancer Care will discuss how her ISO15189-accredited lab has used BSSH to support informatics data analysis as part its routine testing and will share details of why the lab chose this platform over other options.

In particular, Lynn will share how the lab uses the BSSH-hosted DRAGEN (Dynamic Read Analysis for Genomics) apps — Enrichment, Germline, and Somatic — to perform in-depth coverage analyses of a 1,000 cancer gene panel, germline alteration calling, and tumor-normal paired somatic alteration calling, respectively. These apps support about 95 percent of the lab’s analytical needs.

Sponsored by